MF
SLNO

Manchester Financial’s Soleno Therapeutics SLNO Stock Holding History

Manchester Financial’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-133
Closed -$5K – 648
2020
Q3 		$5K Hold
133
– – ﹤0.01% 407
2020
Q2 		$4K Hold
133
– – ﹤0.01% 413
2020
Q1 		$5K Buy
+133
New +$5.66K ﹤0.01% 353

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Manchester Financial's SLNO Position: Q4 2020 in Review

Manchester Financial sold out of Soleno Therapeutics (SLNO) in Q4 2020, closing a stake of 133 shares — an estimated $5K sold.

Manchester Financial first reported a position in SLNO in Q1 2020 and held it in 3 quarters. The position peaked at $5K in Q3 2020. 67 funds tracked by Wall St. Rank hold SLNO as of Q4 2020.

  • Manchester Financial reported no remaining Soleno Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Manchester Financial sold 133 Soleno Therapeutics shares in Q4 2020, an estimated $5K.
  • Manchester Financial first reported a position in Soleno Therapeutics in Q1 2020 and held it in 3 quarters.
  • Manchester Financial's Soleno Therapeutics position peaked at $5K in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2020.

Based on Manchester Financial's 13F filing for Q4 2020, filed 26 Jan 2021.